Clinical trials for preventing post stroke cognitive impairment

被引:33
作者
Ankolekar, Sandeep [1 ]
Geeganage, Chamila [1 ]
Anderton, Peter [1 ]
Hogg, Cheryl [1 ]
Bath, Philip M. W. [1 ]
机构
[1] Univ Nottingham, Div Stroke, Stroke Trials Unit, Nottingham NG5 1PB, England
基金
英国医学研究理事会;
关键词
Antihypertensives; Choline esterase inhibitors; Hypercholesterolemia; Hypertension; Statins; Post stroke dementia; Vascular cognitive impairment; MODERATE ALZHEIMER-DISEASE; VASCULAR DEMENTIA; DOUBLE-BLIND; ATHEROSCLEROSIS; LESIONS; RISK; HYPERTENSION; ATORVASTATIN; MULTICENTER; OUTCOMES;
D O I
10.1016/j.jns.2010.08.052
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Post stroke dementia (PSD) develops in up to 40% of patients and often co-exists with Alzheimer's disease in the elderly. Unsurprisingly, the combination of stroke and dementia is associated with considerable morbidity and mortality, and is devastating to patients and carers. Limited trial evidence suggests that lowering high blood pressure reduces the development of cognitive decline, vascular dementia and PSD, although whether this relates to the magnitude of BP reduction or specific drug classes remains unclear. Biological plausibility and/or existing studies suggest that other types of drug treatments might also be effective, including choline esterase inhibitors, lipid lowering agents, antiplatelet agents, and selective serotonin reuptake inhibitors. Preventing cognitive decline and dementia post stroke is critical and large definitive trials are now needed. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 63 条
[1]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[2]  
[Anonymous], 1991, JAMA, V265, P3255
[3]  
[Anonymous], 2004, Cochrane Database Syst Rev.
[4]  
Antihypertensive T., 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama.288.23.2981, DOI 10.1001/JAMA.288.23.2981]
[5]   IMPACT OF THE TREATMENT OF ISOLATED SYSTOLIC HYPERTENSION ON BEHAVIORAL VARIABLES - RESULTS FROM THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM [J].
APPLEGATE, WB ;
PRESSEL, S ;
WITTES, J ;
LUHR, J ;
SHEKELLE, RB ;
CAMEL, GH ;
GREENLICK, MR ;
HADLEY, E ;
MOYE, L ;
PERRY, HM ;
SCHRON, E ;
WEGENER, V .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (19) :2154-2160
[6]   Clinical trial efforts in Alzheimer disease Why test statins? [J].
Arvanitakis, Zoe ;
Knopman, David S. .
NEUROLOGY, 2010, 74 (12) :945-946
[7]   Galantamine treatment of vascular dementia: A randomized trial [J].
Auchus, A. P. ;
Brashear, H. R. ;
Salloway, S. ;
Korczyn, A. D. ;
De Deyn, P. P. ;
Gassmann-Mayer, C. .
NEUROLOGY, 2007, 69 (05) :448-458
[8]   Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? [J].
Bath, Philip ;
Gray, Laura J. ;
Collier, Timothy .
STROKE, 2009, 40 (03) :888-894
[9]   Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials [J].
Bath, Philip M. W. .
STROKE, 2007, 38 (06) :1911-1915
[10]   Hemostasis and Vascular Dementia [J].
Bath, Philip M. W. ;
Anderton, Peter R. ;
Ankolekar, Sandeep .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (03) :461-463